Amyloids

An amyloid is a protein polymer built on a common architecture: beta strands running perpendicular to the fibril axis, stacked into sheets that run the length of the fibril. The spacing between strands along the axis is close to 4.7 angstroms, and the sheets pack against each other with their side chains interdigitated. That arrangement is what gives amyloid its fiber diffraction pattern, its resistance to detergents and proteases, and its ability to template new molecules onto its ends.

The important consequence is that amyloid is a structural class, not a sequence class. Many proteins with nothing in common can adopt it, which is why one dye, one set of kinetics and one family of assays apply across tau, alpha-synuclein, amyloid-beta, IAPP, transthyretin and others.

Polymorphism, and why it is the whole story for antibodies

A single protein can fold into many distinct amyloid structures. Cryo-electron microscopy of patient-derived filaments has made this concrete: tau filaments from Alzheimer's disease, Pick's disease and corticobasal degeneration have different, disease-specific folds, and alpha-synuclein filaments from different synucleinopathies likewise differ. Fibrils grown in a tube from recombinant protein with a polyanion are not guaranteed to match any of them.

For an antibody program, that is not a technicality. An epitope that is exposed in one polymorph can be buried in another. A binder raised against heparin-induced recombinant tau fibrils may have no purchase on the fold that matters in disease. Whenever the conclusion depends on the fibril, the provenance of that fibril belongs in the claim.

Seeding and templating

Amyloid grows by templating: an existing fibril end imposes its conformation on incoming monomer. This is why seeding shortens the lag phase, why fibril strains propagate their structure, and why the cell-based seeding assays used in neurodegeneration work at all. It also means fragmentation matters, because breaking fibrils creates more ends and accelerates the reaction without any new nucleation.

What is toxic is not settled

Fibril load correlates poorly with clinical severity in several diseases, and soluble oligomers are widely implicated as the damaging species. Oligomers are also transient, heterogeneous and hard to isolate without perturbing them, so the evidence is harder to pin down than for fibrils. For antibody work, the practical position is to state which species your assay reports on, and to avoid implying that reducing ThT signal means reducing toxicity.

Working with amyloid in the lab

• Preparation defines the material. Inducer, ionic strength, agitation, temperature and seeding all select for structure. Write the recipe down and reuse it.
• Sonication changes everything. Fragmenting fibrils to make seeds changes their length distribution and their seeding potency, so it is a variable to control, not a step to gloss over.
• Storage matters. Freeze-thaw and dilution change fibril length and seeding activity. Aliquot, and use consistent handling across an experiment.
• Characterize before you rely on it. ThT tells you cross-beta formed. Electron microscopy tells you what it looks like. A seeding assay tells you it is biologically active. Different questions, different tools.